Carsten Brockmeyer

Meet Carsten Brockmeyer

“For me, my greatest achievement is the development of Binocrit (epoetin alfa), the world’s first complex biosimilar anemia drug,” says Carsten. “I designed the strategy and led the cross-functional team, which succeeded by applying quality-by-design principles for biosimilars from R&D to commercialization. It resulted in the highly successful launch of Binocrit and I think it’s a major game changer in global access to quality medicines.”

www.formycon.com